Empagliflozin and dapagliflozin have some of the strongest cardiovascular and renal outcomes data in medicine. Their longevity relevance is underappreciated and the keyword space is almost empty. Here is the evidence.
SGLT2 inhibitors are discussed less in longevity medicine circles than rapamycin or metformin. The evidence base is stronger than both.
Empagliflozin, dapagliflozin, and canagliflozin were approved as glucose-lowering agents for type 2 diabetes. Their cardiovascular outcomes trials — EMPA-REG OUTCOME, DECLARE-TIMI 58, CANVAS — produced cardiovascular mortality reductions that surprised even their developers. Subsequent trials in heart failure and chronic kidney disease without diabetes extended the benefit to non-diabetic populations.
The mechanism of benefit operates partially independent of glucose lowering — through osmotic diuresis, ketogenesis, renal hemodynamics, and direct cardiac energetic effects. These mechanisms overlap meaningfully with aging biology in ways that have attracted serious scientific attention.
Three aspects of the SGLT2 inhibitor evidence base are relevant to longevity medicine specifically.
Benefit in non-diabetic populations. DAPA-HF, EMPEROR-Reduced, and DAPA-CKD all demonstrated significant benefit in populations where roughly a third to half of participants did not have diabetes. The mechanism is not primarily glycemic. This opens the question of benefit in the broader aging population — currently being investigated in trials.
Renal protection. Chronic kidney disease is both a major driver of mortality and a central aging phenotype. DAPA-CKD demonstrated a 39% reduction in the composite renal and cardiovascular endpoint — one of the largest effect sizes in a modern outcomes trial. Preserving renal function is a direct longevity-relevant endpoint.
Metabolic and energetic effects. SGLT2 inhibitors induce mild ketonemia, reduce visceral adiposity, lower uric acid, and improve mitochondrial efficiency in cardiac tissue. These effects overlap with metabolic interventions studied in aging biology — caloric restriction mimicry, though the degree of overlap remains under investigation.
No published trial has used longevity, healthspan, or biological aging as a primary endpoint for SGLT2 inhibitors. All major outcomes trials enrolled populations with established disease — diabetes, heart failure, or chronic kidney disease.
The evidence for benefit in healthy aging populations without established cardiovascular or renal disease is currently Insufficient. Whether the cardiovascular and renal benefits extrapolate to primary prevention in healthy aging individuals is an open question. Trials in this population are planned but have not yet reported.
SGLT2 inhibitors have the strongest outcomes data of any intervention currently used in longevity medicine — but in specific populations. For patients with type 2 diabetes, heart failure, or chronic kidney disease, the evidence for cardiovascular and renal protection is robust and consistent across multiple large trials.
For healthy aging individuals without these conditions, the evidence base does not currently support routine use for longevity purposes. The mechanistic rationale is compelling and the ongoing trial pipeline is the most watched in this space. This is a drug class worth following closely.